Hostname: page-component-6766d58669-vgfm9 Total loading time: 0 Render date: 2026-05-23T16:51:39.045Z Has data issue: false hasContentIssue false

Critical review of the follow-up protocol for head and neck cancer patients

Published online by Cambridge University Press:  22 April 2019

E Kytö*
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, University of Turku and Turku University Hospital, Finland
E Haapio
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, University of Turku and Turku University Hospital, Finland
H Minn
Affiliation:
Department of Oncology, University of Turku and Turku University Hospital, Finland
H Irjala
Affiliation:
Department of Otorhinolaryngology – Head and Neck Surgery, University of Turku and Turku University Hospital, Finland
*
Author for correspondence: Dr Eero Kytö, Department of Otorhinolaryngology – Head and Neck Surgery, University of Turku and Turku University Hospital, Kiinamyllynkatu 4–8, PL52 20521 Turku, Finland E-mail: eero.kyto@tyks.fi Fax: +358 231 3525

Abstract

Objective

Head and neck cancer follow-up length, interval and content are controversial. Therefore, this study aimed to evaluate the efficacy of the follow-up protocol after curative treatment in head and neck cancer patients.

Method

Clinical data of 456 patients with new malignancy of the head and neck from a tertiary care centre district from 1999 to 2008 were analysed. Time from treatment, symptoms and second-line treatment outcomes of patients with recurrent disease were evaluated.

Results

A total of 94 (22 per cent) patients relapsed during the 5-year follow-up period; 90 per cent of recurrences were found within 3 years. Fifty-six per cent of the patients had subjective symptoms indicating a recurrence of the tumour. All recurrent tumours found during routine follow-up visits without symptoms were found within 34 months after completion of treatment.

Conclusion

Routine follow up after three years is questionable; recurrent disease beyond this point was detected in only 2 per cent of patients. In this study, all late tumour recurrences had symptoms of the disease. Easy access to extra follow-up visits when symptoms occur could cover the need for late follow up.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited, 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable